Enhanced capabilities bring Novasep’s range of specialised drug development technologies within easier reach of North American customers
Novasep, a French supplier of services and technologies for the life sciences industry, is building a new synthesis laboratory and a kilo lab at its facility in Boothwyn, PA, US.
The firm said the extension will allow it to offer both chemistry and purification services and meet increased demand from US customers for closer proximity to its contract manufacturing services.
Novasep will also be able to produce the initial kilogram scale batches of synthetic molecules that are needed for biological testing and preclinical trials.
No financial details about the project have been released.
The new US laboratory greatly enhances Novasep’s global offering for CMO services
Novasep will equip the US facility with 50L reactors. The new laboratory will feature cryogenic capacities as well as standard chemistry. In terms of purification, it will provide North American customers with the complete portfolio of Novasep preparative chromatography processes, such as HPLC (Hipersep), SFC (Supersep) and evaporation. In addition, it will be equipped with analytical tools for PR&D (Process Research and Development), including process safety testing capabilities.
The new laboratory will start operations in May this year.
According to Andrew Brennan, General Manager of Novasep's US operations, the new US laboratory greatly enhances Novasep’s global offering for CMO services and US drug developers will benefit from the extended services that specifically target their needs.
Novasep’s Boothwyn facility has provided purification development services to North American customers for more than 15 years; including screening and process development derived from the firm’s proprietary preparative chromatography technology.